Related Experiment Videos
Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction: a meta-analysis
1Cardiology Unit, 1-McClure, Medical Center Hospital of Vermont, University of Vermont College of Medicine, Burlington 05401.
Insights
Percutaneous transluminal coronary angioplasty (PTCA) significantly reduces mortality in acute myocardial infarction (MI) compared to thrombolysis. This meta-analysis confirms PTCA
Area of Science:
- Cardiology
- Interventional Cardiology
- Evidence-Based Medicine
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) offers advantages over thrombolysis for acute myocardial infarction (MI).
- Previous individual trials lacked the statistical power to demonstrate a definitive survival benefit for PTCA.
- A comprehensive analysis was needed to consolidate evidence and assess PTCA's impact on mortality.
Purpose of the Study:
- To conduct a meta-analysis of randomized controlled trials comparing PTCA and thrombolysis for acute MI.
- To determine if PTCA provides a statistically significant survival advantage over thrombolysis.
- To evaluate PTCA's efficacy across different thrombolytic agents and trial designs.
Main Methods:
- Pooled data from all available randomized, controlled trials (RCTs) of PTCA versus thrombolysis.
- Stratified analyses were performed for trials using streptokinase and tissue plasminogen activator (TPA).
- Mantel-Haenszel odds ratios and Q statistics were used to assess survival benefit and heterogeneity.
Main Results:
- Meta-analysis revealed a significant survival advantage for PTCA across all analyses.
- Odds ratios consistently favored PTCA: all RCTs (0.57), streptokinase trials (0.61), TPA trials (0.52), and all trials (0.51).
- No significant heterogeneity was detected, supporting the robustness of the findings.
Conclusions:
- PTCA is associated with a significant reduction in mortality compared to thrombolysis in acute MI.
- The findings support the widespread adoption of PTCA as a primary treatment for acute myocardial infarction.
- This meta-analysis provides strong evidence for PTCA's superior survival outcomes.
Abstract:
While percutaneous transluminal coronary angioplasty (PTCA) as a primary modality for treating acute myocardial infarction (MI) has been shown to have important advantages over thrombolysis, a survival benefit has not been demonstrated because of the small size of the individual trials. To increase the statistical power to detect a survival benefit, we performed a meta-analysis of trials of PTCA and thrombolysis. We pooled the data for all randomized, controlled trials; randomized, controlled trials stratified according to thrombolytic agent [streptokinase vs. tissue plasminogen activator (TPA)]; and all trials. Pooling was performed by calculating the Mantel-Haenszel odds ratio with the Robins, Greenland, and Breslow estimate of variance. Calculation of the Q statistic was performed to assess heterogeneity. For all four analyses, the odds ratio indicated a significant survival advantage of PTCA over thrombolysis: all randomized controlled trials [0.57, 95% confidence index (CI): 0.48, 0.68)]; streptokinase trials (0.61, 95% CI: 0.43, 0.87); TPA trials (0.52, 95% CI: 0.36, 0.76); all trials (0.51, 95% CI: 0.43, 0.61). The Q statistic was not significant for any of the analyses. The results of our meta-analysis support the hypothesis that PTCA is associated with a significant reduction in mortality compared with thrombolysis.